戈鈺(Ko, Yu) 教授

Email
nancyko@tmu.edu.tw
現   職
臨床藥學學科 教授
藥學院藥事經濟研究中心 主任

學經歷

學 歷

畢業學校與學位[修業時間]
亞利桑那大學藥事經濟 博士
2003/09~2007/06
伊利諾大學芝加哥分校藥學管理 碩士
2001/09~2003/06
臺灣大學藥學系 學士
1995/09~1999/06

本校學術經歷

任職單位與職稱[起迄時間]
臨床藥學學科教授
2020/02/01~
臨床藥學學科副教授
2015/02/01~2020/01/31

本校兼職教學行政經歷

服務單位與職稱[起迄時間]
藥學院藥事經濟研究中心主任
2016/08/01 ~
(舊)臨床藥物基因體學暨蛋白質體學碩士學位學程副教授
2015/08/01 ~

其它經歷

任職單位與職稱[起迄時間]
新加坡大學助理教授
2009/02~2014/06
新加坡大學博士後研究員
2007/06~2009/01

專長與研究領域

學門領域
藥學
學術專長

論文著作

清冊下載


1. 2024 Fang TY,Lin PH,Ko Y,Wu CC,Wang H,Liao WC, Wang PC. Validation of the Chinese Version of the Speech, Spatial, and Qualities of Hearing Scale for Parents and Children . Ear Hear .2024 ;(45):1362-1368

2. 2024 Tseng TH,Chiang SC,Hsu JC,Ko Y. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan . PLoS One .2024 ;(19):e0303294

3. 2024 Lin TH,Lin PH,Fang TY,Wu CC,Wang PC,Ko Y. Cost-Utility Analysis of Bilateral Cochlear Implants for Children With Severe-to-Profound Sensorineural Hearing Loss in Taiwan . Ear Hear .2024

4. 2024 Hsu SW,Chiang SC,Hsu JC,Ko Y. Validation of risk models for predicting febrile neutropenia among breast cancer patients receiving chemotherapy: a real-world study . Clin Ther .2024

5. 2024 Chang YW,Kuo CK,Chang CL,Hsu JC,Ko Y. Effectiveness and Safety of Regorafenib and TAS-102 in Patients with Metastatic Colorectal Cancer: A Nationwide Population-Based Study in Taiwan . Cancer Res Treat .2024

6. 2023 Hsu SW,Chiang SC,Hsu JC,Ko Y. Prescription patterns of granulocyte colony-stimulating factors in patients with breast cancer: A real-world study . PLoS One .2023 ;(18):e0288642

7. 2023 Chen YW,Lin PH,Fang TY,Wu CC,Wang PC,Wang H, Ko Y. Health Utilities of Bilateral Severe-to-Profound Hearing Loss with Assistive Devices . Healthcare (Basel) .2023 ;(11):1649

8. 2022 Yeh Y,Chen C,Ko Y. Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: A systematic review and meta-analysis . J Cancer Res Ther .2022 ;(18):1061-1072

9. 2022 Chen X,Wang CY,Ko Y. An investigation of physicians' prescribing behaviors related to antidiabetic agents for Type 2 diabetes mellitus patients and associated factors in Taiwan . Curr Med Res Opin .2022

10. 2022 Wu YS,Chen C,Wang LC,Jian LS,Ko Y. Talent cultivation in health technology assessment: an expert survey . BMC Med Educ .2022 ;(22):157-162

11. 2021 Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk . Sci Rep .2021 ;(11):1430

12. 2021 Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan . Breast .2021 ;(57):18-25

13. 2021 An evaluation of the healthcare costs associated with adverse events in patients with breast cancer. . Int J Health Plann Manage .2021 ;(36):1465-1475

14. 2021 An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study. . Medicine (Baltimore) .2021 ;(100):e27567

15. 2021 Chen CC,Chen JH,Chen CL,Lai TJ,Ko Y. Health Utilities in Patients with Type 2 Diabetes in Taiwan . Healthcare (Basel) .2021 ;(9):1672-1680

16. 2021 Poon SY,Hsu JC,Ko Y,Chiang SC. Assessing Knowledge and Attitude of Healthcare Professionals on Biosimilars: A National Survey for Pharmacists and Physicians in Taiwan . Healthcare (Basel) .2021 ;(9):1600-1610

17. 2020 Pao CH,Ko Y. An assessment of the psychometric properties of the Chinese version of the Gout Impact Scale . Curr Med Res Opin .2020 ;(36):17-21

18. 2020 Chou TC,Chiang SC,Ko Y. Health state utilities for metastatic breast cancer in Taiwan . Breast .2020 ;(51):57-64

19. 2020 Chien CL,Chen YC,Malone DC,Peng YL,Ko Y. Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. . Curr Med Res Opin .2020 ;(10):1619-1626

20. 2020 Chen CC,Chen CL,Ko Y. The Misconceptions and Determinants of Diabetes Knowledge in Patients with Diabetes in Taiwan. . J Diabetes Res .2020

21. 2020 Chen YJ,Chen FL,Chen JH,Wu MM,Chien DS,Ko Y. Costs and length of sepsis-related hospitalizations in Taiwan. . Medicine .2020 ;(99):e20476

22. 2020 Diaby V,Alqhtani H,van Boemmel-Wegmann S,Wang CY,Ali AA,Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. . Breast .2020 ;(49):141-148

23. 2020 Lin HW,Chang EH,Ko Y,Wang CY,Wang YS,Mafruhah OR, Wu SH, Chen YC, Huang YM. Conceptualization, Development and Psychometric Evaluations of a New Medication-Related Health Literacy Instrument: The Chinese Medication Literacy Measurement . Int J Environ Res Public Health .2020 ;(17):6951-5967

24. 2020 Wang LC,Kuo CN,Ko Y. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in treating HER-2 positive advanced breast cancer in Taiwan . Breast J .2020

25. 2019 Lee YY,Kuo LN,Chen JH,Lin YC,Chen LF,Ko Y. Prescribing patterns and healthcare costs of gout . Curr Med Res Opin .2019 ;(35):1051-1058

26. 2019 Cheng SW,Wang CY,Ko Y. Costs and Length of Stay of Hospitalizations due to Diabetes-Related Complications . J Diabetes Res .2019

27. 2019 Chen YJ,Chen FL,Chen JH,Wu MTM,Chen YL ,Chu YW, Chien DS, Ko Y. Epidemiology of Sepsis in Taiwan . Medicine .2019 ;(98):e15725

28. 2019 Tseng KH,Chang EH,Ko Y. An investigation of the determinants for community pharmacists' positive image and the needs for community pharmacists' services in Taiwan . Int J Health Plann Manage .2019

29. 2018 Chi NF,Wang Y,Chien LN,Chien SC,Ko Y. Healthcare costs and utilization of dabigatran compared to warfarin for secondary stroke prevention in patients with non-valvular atrial fibrillation: A retrospective population study . Med Care .2018 ;(56):410-415

30. 2018 Lee YY,Tang CH,Chen JH,Kuo LN,Ko Y. Evaluation of healthcare costs and utilization for patients with gout: a population-based matched cohort study . Curr Med Res Opin .2018 ;(34):735-740

31. 2018 Lin YJ,Wang CY,Cheng SW,Ko Y. Patient preferences for diabetes-related complications in Taiwan . Curr Med Res Opin .2018 ;(35):7-13

32. 2018 Siaw MYL,Malone DC,Ko Y,Lee JY. Cost-effectiveness of multidisciplinary collaborative care versus usual care in the management of high-risk patients with diabetes in Singapore: Short-term results from a randomized controlled trial . J Clin Pharm Ther .2018 ;(43):775-783

33. 2018 Lin YJ,Wang CY,Chang EH,Cheng SW,Ko Y. Translation, revision, and validation of the Chinese version of the Satisfaction with Oral Anti-Diabetic Agent Scale (C-SOADAS) in patients with type 2 diabetes mellitus . Patient Prefer Adherence .2018 ;(12):667-672

34. 2018 Cheng SW,Wang CY,Chen JH,Ko Y. Healthcare costs and utilization of diabetes-related complications in Taiwan: A claims database analysis . Medicine (Baltimore) .2018 ;(97):e11602-e11608

35. 2017 Yeh YC,Lin HW,Chang EH,Huang YM,Chen YC,Wang CY, Liu JW, Ko Y. Development and validation of a Chinese medication literacy measure . Health Expectations .2017 ;(20):1296-1301

36. 2017 Siaw MYL,Ko Y,Malone DC,Tsou KYK,Lew YJ,Foo D, Tan E, Chan SC, Chia A, Sinaram SS, Goh KC, Lee JY. Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial . J Clin Pharm Ther .2017 ;(42):475-482

37. 2017 Ng CS,Lau TC,Ko Y. Cost of Osteoporotic Fractures in Singapore . Value Health Reg Issues .2017 ;(12):27-35

38. 2016 Wang Y,Yeo QQ,Ko Y. Economic evaluations of pharmacist-managed services in people with diabetes mellitus: a systematic review . Diabet Med .2016 ;(33):421-427

39. 2015 Shuyu Ng C,Toh MP,Ko Y,Yu-Chia Lee J. Direct medical cost of type 2 diabetes in singapore . PLoS One .2015 ;(10):e01227

40. 2015 Wang Y,Xie F,Kong MC,Lee LH,Ng HJ,Ko Y. Patient-reported health preferences of anticoagulant-related outcomes . Journal of Thrombosis and Thrombolysis .2015 ;(40):268-273

41. 2015 Ng CS,Toh MP,Ng J,Ko Y. Direct medical cost of stroke in Singapore . Int J Stroke .2015 ;(10):75-82

42. 2014 Wang Y,Kong MC,Lee LH,Ng HJ,Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control . Thromb Res .2014 ;(133):550-554

43. 2014 Chan A,Soh D,Ko Y,Huang YC,Chiang J. Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients . Support Care Cancer .2014 ;(22):1875-1881

44. 2014 Tan XY,Aung MM,Ngai MI,Xie F,Ko Y. Assessment of preference for hormonal treatment–related health states among patients with breast cancer . ViHRI .2014 ;(3):27-32

45. 2014 Ko Y,Gwee YS,Huang YC,Chiang J,Chan A. Costs and length of stay of drug-related hospital admissions in cancer patients . Clin Ther .2014 ;(3):588-592

46. 2014 Ng CS,Lee JY,Toh MP,Ko Y. Cost-of-illness studies of diabetes mellitus: A systematic review . Diabetes Res Clin Pract .2014 ;(105):151-163

47. 2014 Wang Y,Xie F,Kong MC,Lee LH,Ng HJ,Ko Y. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation . Cardiovasc Drugs Ther .2014 ;(28):575-585

48. 2013 Wang Y,Kong MC,Ko Y. Comparison of three medication adherence measures in patients taking warfarin . J Thromb Thrombolysis .2013 ;(36):416-421

49. 2013 Ko Y,Lo NN,Yeo SJ,Yang KY,Yeo W,Chong HC, Thumboo J. Comparison of the responsiveness of the SF-36, the Oxford Knee Score, and the Knee Society Clinical Rating System in patients undergoing total knee replacement . Qual Life Res .2013 ;(22):2455-2459

50. 2013 Ko Y,Devi Balasubramanian,Wong L,Tan ML,Lee E,Tang WE, Chan SC, Tan ASL, Toh MP HS. Health literacy and its association with disease knowledge and control in patients with hypertension in Singapore . Intl J Cardiology .2013 ;(168):e116-117

51. 2012 Ko Y,Lee JY,Toh MP,Tang WE,Tan AS. Development and validation of a general health literacy test in Singapore . Health Promot Int .2012 ;(27):45-51

52. 2012 Low JJ,Ko Y,Ilancheran A,Zhang XH,Singhal PK,Tay SK. Health and economic burden of HPV-related diseases in Singapore . Asian Pac J Cancer Prev .2012 ;(13):305-308

53. 2012 Shih V,Chan A,Xie F,Ko Y. Health state utility assessment for breast cancer . ViHRI .2012 ;(1):93-97

54. 2012 Shih V,Chan A,Xie F,Ko Y. Economic evaluation of anastrozole versus tamoxifen for early stage breast cancer in Singapore . ViHRI .2012 ;(1):46-53

55. 2012 Shim YT,Lee J,Toh MP,Tang WE,Ko Y. Health-related quality of life and glycaemic control in patients with Type 2 diabetes mellitus in Singapore . Diabet Med .2012 ;(29):e241-248

56. 2012 Wang Y,Lee J,Tang WE,Toh MP,Ko Y. Validity and reliability of a self-reported meas ure of medication adherence in patients with Type 2 diabetes mellitus in Singapore . Diabet Med .2012 ;(29):e338-344

57. 2012 Ko Y,Tan SL,Chan A,Wong YP,Yong WP,Ng RCH, Lim SW, Salim A. Prevalence of the co-prescription of clinically important interacting drug combinations involving oral anticancer agents: a retrospective database study . Clin Ther .2012 ;(34):1696-1704

58. 2012 Wang Y,Kong MC,Ko Y. Psychometric properties of the 8-item Morisky Medication Adherence Scale in patients taking warfarin . Thromb Haemost .2012 ;(108):789-795

59. 2012 Koomanan N,Ko Y,Yong WP,Ng R,Wong YP,Lim SW, Salim A, Chan A. Clinical impact of drug-drug interaction between aspirin and prednisolone at a cancer center . Clin Ther .2012 ;(34):2259-2267

60. 2011 Wong S,Lee J,Ko Y,Chong MF,Lam CK,Tang WE. Perceptions of insulin therapy amongst Asian patients with diabetes in Singapore . Diabet Med .2011 ;(28):206-211

61. 2011 Ko Y,Narayanasamy S,Wee HL,Lo NN,Yeo SJ,ang KY, Yeo W, Chong HC, Thumboo J. Health-related quality of life after total knee replacement or unicompartmental knee arthroplasty in an urban asian population . Value Health .2011 ;(14):322-328

62. 2011 Lua HL,Sklar G,Ko Y. Identification and physicians' views of their commonly-used drug information sources in Singapore . Int J Clin Pharm .2011 ;(33):772-778

63. 2009 Lim YJ,Chan SY,Ko Y. Stigma and health-related quality of life in Asian adults with epilepsy . Epilepsy Res .2009 ;(87):107-119

64. 2009 Luo N,Ko Y,Johnson JA,Coons SJ. The association of survey language (Spanish vs. English) with Health Utilities Index and EQ-5D index scores in a United States population sample . Qual Life Res .2009 ;(18):1377-1385

65. 2009 Chan A,Tan SH,Wong CM,Yap KYL,Ko Y. Clinically significant drug-drug interactions between oral anticancer agents and non-anticancer agents: a Delphi survey of oncology pharmacists . Clin Ther .2009 ;(31):2379-2386

66. 2009 Wong PS,Ko Y,Sklar GE. Identification and evaluation of pharmacists' commonly used drug information sources . Ann Pharmacother .2009 ;(43):347-352

67. 2009 Ho CH,Ko Y,Tan ML. Patient needs and sources of drug information in Singapore- is the internet replacing former sources? . Ann Pharmacother .2009 ;(43):732-739

68. 2009 Ko Y,Lo NN,Yeo SJ,Yang KY,Yeo W,Chong HC, Thumboo J. Rasch analysis of the Oxford Knee Score . Osteoarthritis Cartilage .2009 ;(17):1163-1169

69. 2008 Ko Y,Malone DC,Skrepnek GH,Armstrong EP,Murphy JE,Abarca J, Rehfeld RA, Reel SJ, Woosley RL. Prescribers' knowledge of and source for drug-drug interaction information . Drug Saf .2008 ;(31):525-536

70. 2008 Wong CM,Ko Y,Chan A. Clinically significant drug-drug interactions between oral anticancer agents and non-anticancer agents: profiling and comparison of two drug compendia . Ann Pharmacother .2008 ;(42):1737-1748

71. 2008 Ko Y,Malone DC,D' Agostino JV,Skrepnek GH,Armstrong EP,Brown M, Woosley RL. Potential determinants of prescribers' drug-drug interaction knowledge . Res Social Adm Pharm .2008 ;(4):355-366

72. 2007 Ko Y,Abarca J,Malone DC,Dare DC,Geraets D,Houranieh A, Jones WN, Nichol WP, Schepers GP, Wilhardt M. Practitioners' views on computerized drug-drug interaction alerts in the VA system . J Am Med Inform Assoc .2007 ;(14):56-64

73. 2007 Mahmood M,Malone DC,Skrepnek GH,Abarca J,Armstrong EP,Murphy JE, Grizzle AJ, Ko Y, Woosley RL. Potential drug-drug interactions within Veterans Affairs medical centers . Am J Health Syst Pharm .2007 ;(64):1500-1505

74. 2007 Grizzle AJ,Mahmood M,Ko Y,Murphy JE,Armstrong EP,Skrepnek GH, Jones WN, Schepers GP, Nichol WP, Houranieh A, Dare DC, Hoey CT, Malone DC. Reasons Provided by Prescribers when overriding drug-drug interaction alerts . Am J Manag Care .2007 ;(13):573-580

75. 2006 Brown M,Frost R,Ko Y. Diagramming patients’ views of root causes of adverse drug events in ambulatory care: an online tool for planning education and research . Patient Educ Couns .2006 ;(62):302-315

76. 2006 Ko Y,Coons SJ. Self-reported chronic conditions and EQ-5D index scores in the US adult population . Curr Med Res Opin .2006 ;(22):2065-2071

77. 2006 Ko Y,Brown M,Woosley R,Woosley R. Development of a prescription medication information webliography for consumers . J Gen Intern Med .2006 ;(21):1313-1316

78. 2006 Ko Y,Malone DC,Armstrong EP. A pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder . Pharmacotherapy .2006 ;(26):1694-1702

79. 2005 Ko Y,Lin SJ,Salmon JW,Bron MS. The impact of urinary incontinence on quality of life of the elderly . Am J Manag Care .2005 ;(11):S103-S111

80. 2005 Ko Y,Coons SJ. An examination of self-reported chronic conditions and health status in the 2001 Medicare Health Outcomes Survey . Curr Med Res Opin .2005 ;(21):1801-1808

研究計畫

計畫名稱
107 台灣血友病患醫療資源利用及治療型態分析研究計畫
補助單位
傑特貝林有限公司

計畫名稱
105 建置常見疾病的本土藥物經濟模型並運用醫療科技評估方法探討健保給付醫療措施之效益
補助單位
財團法人醫藥品查驗中心

計畫名稱
104 XIGDUE® (Dapagliflozin/Metformin) 藥物經濟學研究計畫
補助單位
台灣阿斯特捷利康股份有限公司

計畫名稱
104 痛風之效果研究:經濟影響、人文負擔、以及藥事經濟評估
補助單位
科技部

計畫名稱
104 新聘教師研究補助
補助單位
臺北醫學大學

計畫名稱
103 Febuxostat 和 Allopurionol 用於慢性腎臟病病人的成本效益分析
補助單位
台北市立萬芳醫院委託財團法人私立臺北醫學大學辦理